This company has been marked as potentially delisted and may not be actively trading. Aileron Therapeutics (ALRN) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Aileron Therapeutics (NASDAQ:ALRN)CurrentInstitutional OwnershipPercentage90.89%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$11.15MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$55.95K Get ALRN Insider Trade Alerts Want to know when executives and insiders are buying or selling Aileron Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ALRN Institutional Buying and Selling by Quarter Aileron Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024Geode Capital Management LLC229,817$814K0.0%+34.8%1.061% 11/4/2024Sigma Planning Corp212,410$752K0.0%+68.3%0.980% 10/29/2024 KG&L Capital Management LLC13,000$46K0.0%N/A0.060% 9/17/2024University of Texas Texas AM Investment Management Co.1,777,827$4.93M1.0%N/A8.225% 8/20/2024Nantahala Capital Management LLC464,367$1.29M0.1%+82.1%2.148% 8/9/2024Renaissance Technologies LLC24,864$69K0.0%-44.8%0.115% 8/9/2024Warberg Asset Management LLC31,354$86K0.0%N/A0.145% 8/2/2024University of Texas Texas AM Investment Management Co.1,777,827$4.93M1.9%N/A8.225% 5/13/2024Texas Capital Bank Wealth Management Services Inc26,171$174K0.0%+65.9%0.155% 2/8/2024Texas Capital Bank Wealth Management Services Inc15,773$48K0.0%N/A0.323% Get the Latest News and Ratings for ALRN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/1/2024Sigma Planning Corp16,580$51K0.0%N/A0.339% 2/15/2023Alerce Investment Management L.P.830,466$1.97M2.3%-95.0%18.288% 2/10/2023Blair William & Co. IL67,867$161K0.0%-94.5%1.495% 1/31/2023KCK LTD.22,341$53K0.1%-95.0%0.492% 10/31/2022KCK LTD.446,817$101K0.2%-30.9%0.492% 4/25/2022Bailard Inc.128,010$66K0.0%N/A0.141% 2/14/2022Blair William & Co. IL1,067,489$601K0.0%+32.9%1.179% 2/11/2022KCK LTD.646,817$362K0.3%N/A0.714% 2/10/2022Acadian Asset Management LLC85,274$47K0.0%N/A0.094% 2/4/2022 Envestnet Asset Management Inc.136,760$77K0.0%+152.4%0.151% 2/2/2022PVG Asset Management Corp50,300$28K0.1%+113.5%0.056% 1/27/2022Morgan Jess S & Co. Inc.100,000$56K0.0%+33.3%0.110% 11/16/2021Keebeck Wealth Management LLC76,000$78K0.0%-51.2%0.084% 11/12/2021Renaissance Technologies LLC734,721$749K0.0%-28.7%0.811% 11/9/2021Morgan Jess S & Co. Inc.75,000$76K0.1%N/A0.083% 11/9/2021Barclays PLC25,279$26K0.0%+235.4%0.028% 11/9/2021 JFS Wealth Advisors LLC31,807$32K0.0%N/A0.035% 10/26/2021Game Plan Financial Advisors LLC127,000$130K0.1%+27.0%0.140% 8/17/2021Boothbay Fund Management LLC393,015$491K0.0%+11.8%0.434% 8/16/2021State Street Corp71,200$89K0.0%N/A0.079% 8/13/2021Renaissance Technologies LLC1,031,128$1.29M0.0%-17.5%1.142% 8/13/2021Geode Capital Management LLC766,813$958K0.0%+34.1%0.849% 8/13/2021Vanguard Group Inc.3,440,633$4.30M0.0%-5.9%3.809% 8/12/2021Blair William & Co. IL688,044$860K0.0%+99.1%0.762% 8/4/2021 Envestnet Asset Management Inc.34,654$43K0.0%+45.1%0.038% 5/21/2021Citadel Advisors LLC46,830$67K0.0%N/A0.052% 5/19/2021Virtu Financial LLC146,341$209K0.0%+746.6%0.162% 5/18/2021BVF Inc. IL5,265,555$7.53M0.3%N/A5.829% 5/18/2021Citadel Advisors LLC46,830$67K0.0%N/A0.052% 5/17/2021Ikarian Capital LLC2,800,000$4.00M0.1%N/A3.100% The Man I Turn to In Times Like This (Ad)A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.Market chaos? Hear Tilson’s take now5/13/2021Renaissance Technologies LLC1,250,500$1.79M0.0%+97.1%1.385% 5/13/2021Blair William & Co. IL345,594$494K0.0%+29.0%0.383% 5/12/2021Northern Trust Corp127,883$183K0.0%+378.0%0.142% 5/12/2021Geode Capital Management LLC571,738$817K0.0%+149.3%0.633% 5/12/2021Satter Management CO. L.P.16,609,449$23.75M10.5%+118.3%18.394% 5/11/2021Acadian Asset Management LLC134,419$192K0.0%+30.8%0.149% 5/5/2021Wade G W & Inc.100,993$144K0.0%N/A0.112% 5/4/2021 Envestnet Asset Management Inc.23,886$34K0.0%+105.2%0.026% 4/28/2021Game Plan Financial Advisors LLC77,500$112K0.1%+13.1%0.086% (Data available from 1/1/2016 forward) ALRN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALRN shares? During the previous two years, the following institutional investors and hedge funds held shares of Aileron Therapeutics shares: University of Texas Texas AM Investment Management Co. ($4.93M), Nantahala Capital Management LLC ($1.29M), Geode Capital Management LLC ($814K), Sigma Planning Corp ($752K), Texas Capital Bank Wealth Management Services Inc ($174K), Warberg Asset Management LLC ($86K), and Renaissance Technologies LLC ($69K).Learn more on ALRN's institutional investors. What percentage of Aileron Therapeutics stock is owned by institutional investors? 90.89% of Aileron Therapeutics stock is owned by institutional investors. Learn more on ALRN's institutional investor holdings. Which institutional investors have been buying Aileron Therapeutics stock? The following institutional investors have purchased Aileron Therapeutics stock in the last 24 months: University of Texas Texas AM Investment Management Co. ($3.56M), Nantahala Capital Management LLC ($209.37K), Sigma Planning Corp ($102.77K), Geode Capital Management LLC ($59.37K), Warberg Asset Management LLC ($31.35K), Texas Capital Bank Wealth Management Services Inc ($26.17K), and KG&L Capital Management LLC ($13K). How much institutional buying is happening at Aileron Therapeutics? Institutional investors have bought a total of 3,997,681 shares in the last 24 months. This purchase volume represents approximately $11.24M in transactions. Which Aileron Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Aileron Therapeutics stock in the last 24 months: Renaissance Technologies LLC ($20.20K). How much institutional selling is happening at Aileron Therapeutics? Institutional investors have sold a total of 20,200 shares in the last 24 months. This volume of shares sold represents approximately $55.95K in transactions. Related Companies Prime Medicine Major Shareholders Neurogene Major Shareholders Genfit Major Shareholders Eledon Pharmaceuticals Major Shareholders Voyager Therapeutics Major Shareholders Tevogen Bio Major Shareholders Kodiak Sciences Major Shareholders Canopy Growth Major Shareholders Esperion Therapeutics Major Shareholders INmune Bio Major Shareholders This page (NASDAQ:ALRN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
